

Calvin Q Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11158056/publications.pdf>

Version: 2024-02-01

44
papers

2,752
citations

361045

20
h-index

264894

42
g-index

44
all docs

44
docs citations

44
times ranked

2284
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. <i>Gut</i> , 2022, 71, 798-806.	6.1	7
2	The role of gut microbiota in hepatitis B disease progression and treatment. <i>Journal of Viral Hepatitis</i> , 2022, 29, 94-106.	1.0	9
3	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. <i>Hepatology Communications</i> , 2022, 6, 1881-1894.	2.0	7
4	The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B. <i>Antiviral Therapy</i> , 2022, 27, 135965352210766.	0.6	2
5	Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1061-1063.	2.4	2
6	Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. <i>Liver International</i> , 2021, 41, 1498-1508.	1.9	24
7	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , 2021, 16, e0251552.	1.1	4
8	The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study. <i>BMC Medicine</i> , 2021, 19, 148.	2.3	7
9	Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1377-1386.	1.9	29
10	The Role of Earlier Use of Immunoprophylaxis in Preventing Mother-to-Child Transmission of Hepatitis B. <i>Clinical Infectious Diseases</i> , 2020, 73, 165-166.	2.9	1
11	The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy. <i>Journal of Medical Virology</i> , 2020, 92, 3381-3389.	2.5	8
12	Hepatitis B "management of acute infection and active inflammation in pregnancy" a hepatologist's perspective. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 68, 54-65.	1.4	6
13	Letter: tenofovir disoproxil fumarate is safe for prevention of mother-to-child transmission of hepatitis B virus. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 477-478.	1.9	1
14	Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C. <i>Liver Research</i> , 2019, 3, 75-79.	0.5	0
15	Letter: put on your thinking cap " tenofovir disoproxil fumarate for the prevention of vertical transmission of hepatitis B virus. Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 824-825.	1.9	0
16	Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 147-154.	1.1	4
17	Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 211-217.	1.9	35
18	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. <i>Digestive Diseases and Sciences</i> , 2019, 64, 358-366.	1.1	7

#	ARTICLE	IF	CITATIONS
19	The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2018, 113, 686-693.	0.2	32
20	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	1.8	291
21	Update in the Management of Chronic Hepatitis B in Pregnancy. <i>Current Hepatology Reports</i> , 2018, 17, 475-484.	0.4	2
22	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	41
23	Viral factors for HBV mother-to-child transmission. <i>Hepatology International</i> , 2017, 11, 476-480.	1.9	23
24	Clinical Features of Chronic Hepatitis B in Treatment-naïve Asian Patients With Positive HBeAg and Coexisting Precore and/or Basal Core Promoter Mutations. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 261-267.	1.1	8
25	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	3.7	377
26	Prevention of Peripartum Hepatitis B Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 1496-1498.	13.9	10
27	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1297-1304.	0.2	39
28	Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. <i>New England Journal of Medicine</i> , 2016, 374, 2324-2334.	13.9	460
29	Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2015, 21, 5524.	1.4	14
30	Clinical Presentation and Disease Phases of Chronic Hepatitis B Using Conventional Versus Modified ALT Criteria in Asian Americans. <i>Digestive Diseases and Sciences</i> , 2014, 59, 865-871.	1.1	13
31	Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. <i>Hepatology</i> , 2014, 60, 468-476.	3.6	164
32	Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. <i>Journal of Hepatology</i> , 2014, 60, 523-529.	1.8	97
33	Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings. <i>PLoS ONE</i> , 2014, 9, e89789.	1.1	20
34	Long-Term Therapy with Nucleoside/Nucleotide Analogues for Chronic Hepatitis B in Asian Patients. <i>Antiviral Therapy</i> , 2013, 18, 841-852.	0.6	14
35	Hepatitis Outreach Network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities. <i>Journal of Hepatology</i> , 2013, 58, 890-897.	1.8	58
36	Cesarean Section Reduces Perinatal Transmission of Hepatitis B Virus Infection From Hepatitis B Surface Antigen-Positive Women to Their Infants. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1349-1355.	2.4	99

#	ARTICLE	IF	CITATIONS
37	Antiviral Therapy for Chronic Hepatitis B in Pregnancy. <i>Seminars in Liver Disease</i> , 2013, 33, 138-146.	1.8	62
38	Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2423-2429.	1.1	106
39	High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1047-1050.e1.	2.4	14
40	Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 520-526.	2.4	145
41	An Algorithm for Risk Assessment and Intervention of Mother to Child Transmission of Hepatitis B Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 452-459.	2.4	224
42	Barriers to Screening for Hepatitis B Virus Infection in Asian Americans. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3163-3171.	1.1	73
43	The Management of Chronic Hepatitis B in Asian Americans. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3143-3162.	1.1	69
44	Natural History and Clinical Consequences of Hepatitis B Virus Infection. <i>International Journal of Medical Sciences</i> , 2005, 2, 36-40.	1.1	144